Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes how anifrolumab, used beyond trial-eligible populations, led to significant clinical and serological recovery in a 45-year-old woman with organ-threatening systemic lupus erythematosus complicated by infection and resistant to conventional treatments like cyclophosphamide and rituximab.

In this case report, two patients with coexisting systemic lupus erythematous and neuromyelitis optica spectrum disorder achieved remission of SLE activity using an anti-CD19 monoclonal antibody.

In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.

In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.

In this case report, a 64-year-old woman diagnosed with both NMOSD and SLE showed mild improvement in vision and recovered from thrombocytopenia after treatment with glucocorticoids and Rituximab, highlighting the importance of accurate diagnosis and tailored treatment for overlapping autoimmune disorders.